Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection
Figure 2
Synergistic activation of HIV-1 production by prostratin and clinically used HDACIs.
U1 (panels A, B and C), J-Lat 15.4 (panels D, E and F) or J-Lat 8.4 (panels G, H and I) cells were mock-treated or treated with TNFα (10 ng/ml) (panels A, D and G), PMA (20 nM) (panels B, E and H), prostratin (5 µM) (panels C, F and I) alone or in combination with different HDACIs [VPA (2.5 mM), SAHA (2.5 µM), TSA (500 nM), NaBut (5 mM) or MS-275 (5 µM)]. At 24 h posttreatment, viral production was estimated by measuring CA-p24 antigen concentration in culture supernatants. The mock-treated value was arbitrarily set at a value of 1. Each value is the mean±SE from two (for the J-Lat 15.4 and 8.4 cell lines) or three (for the U1 cell lines) separate experiments performed in triplicate.